VCYT insider Form 4 shows director stock sale at about $50

Rhea-AI Filing Summary

Veracyte, Inc. (VCYT) reported an insider stock sale by one of its directors. According to the Form 4, the director sold 1,106 shares of Veracyte common stock on 11/25/2025 at a weighted average price of $50.2493 per share, with individual trade prices ranging from $50.005 to $50.66. Following this transaction, the director now beneficially owns 29,362 shares of Veracyte common stock in direct ownership.

The filing notes that these transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 9, 2024. Such plans allow insiders to sell shares according to a preset schedule or conditions, helping separate trading activity from day-to-day decisions about the company.

Insider Trade Summary

Net Seller: 1,106 shares ($55,576)

Net Sell 1 txn

Insider JONES EVAN/ FA

Role Director

Sold 1,106 shs ($56K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,106	$50.2493	$56K

Holdings After Transaction: Common Stock — 29,362 shares (Direct)

Footnotes (1)

1. The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 9, 2024. Represents weighted average sales price. Sale prices for the transactions range from $50.005 to $50.66. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JONES EVAN/ FA

(Last) (First) (Middle)

6000 SHORELINE COURT

SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [ VCYT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/25/2025		S(1)		1,106	D	$50.2493(2)	29,362	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 9, 2024.

2. Represents weighted average sales price. Sale prices for the transactions range from $50.005 to $50.66. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

Remarks:

	/s/ Jonathan Wygant, as attorney-in-fact	11/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Veracyte (VCYT) report in this Form 4?

The Form 4 reports that a director of Veracyte, Inc. sold 1,106 shares of Veracyte common stock on 11/25/2025.

At what price were the Veracyte (VCYT) shares sold in this insider trade?

The shares were sold at a weighted average price of $50.2493 per share, with individual sale prices ranging from $50.005 to $50.66.

How many Veracyte (VCYT) shares does the insider own after the sale?

After the reported transaction, the director beneficially owns 29,362 shares of Veracyte common stock in direct ownership.

Was the Veracyte (VCYT) insider sale made under a Rule 10b5-1 plan?

Yes. The filing states the transactions were made under a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2024.

What does a Rule 10b5-1 trading plan mean for Veracyte (VCYT) insider sales?

A Rule 10b5-1 plan allows insiders to sell shares according to a pre-established plan, helping separate their trading activity from ongoing corporate information and decisions.

What role does the reporting person hold at Veracyte (VCYT)?

The reporting person is identified as a director of Veracyte, Inc., with the Form 4 indicating the relationship as Director and direct ownership of the reported shares.